Articles

Interim Analysis of BATON-CRC: Tivozanib plus mFOLFOX6 in Patients with Metastatic Colorectal Cancer

ESMO 2014 - Gastrointestinal and Head & Neck Cancer, ESMO

Conference Correspondent

Updated STRIDE and STAND Trial Results: Optimal Sipuleucel-T Use in Metastatic Prostate Cancer

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent

Androgen Receptor and CYP17A1 Copy Number Variations as Predictors of Outcomes in Patients with Metastatic Prostate Cancer Receiving Abiraterone

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent

Adding Docetaxel to ADT Significantly Improves Survival versus ADT Alone in Patients with High-Volume Metastatic Prostate Cancer

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent

Early PSA Response as a Prognostic Factor in Metastatic Prostate Cancer

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent

Emerging Agents for Metastatic Prostate Cancer: Galeterone, Selinexor, and ARN-509

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent

Sequencing Abiraterone Acetate, Cabazitaxel, and Enzalutamide in Post-Docetaxel mCRPC: Exploiting Efficacy and Avoiding Cross-Resistance

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent

Arzerra (Ofatumumab) Receives FDA Approval for Patients with Previously Untreated Chronic Lymphocytic Leukemia for Use in Combination with Chlorambucil

By Lisa A. Raedler, PhD, RPh

September 2014, Vol 5, No 7

Chronic lymphocytic leukemia (CLL), the most common type of leukemia in adults, is a cancer that predominantly affects the B-cell lymphocytes.

BRAF Protein Expression Potential New Marker for Mortality Risk in Melanoma

By Rosemary Frei, MSc

September 2014, Vol 5, No 7

Toronto, Ontario—BRAF protein expression is correlated with melanoma progression and poor patient survival, according to recent studies that were reviewed at the 2014 Canadian Dermatology Association annual conference.

Comparative Effectiveness Research Helps Define Value in Cancer Care

By Wayne Kuznar

Comparative Effectiveness Research

September 2014, Vol 5, No 7

Los Angeles, CA—Comparative effectiveness research (CER) can be beneficial to determining value in cancer therapies, but challenges remain in applying this approach in oncology.

Page 215 of 329